



UK CLL Forum Clinical Sciences Day

Personalised and Supportive Care in CLL

Thursday 2nd October 2014

Brunei Gallery, School of Oriental & African Studies, Thornhaugh Street, London WC1H 0XG

Platinum:



Gold:



Supporters:



Educational Grants:



09.15 *Registration and Coffee*

Targeted treatment in 2014

Chair: Dr Helen McCarthy

10.00 Clonal (and subclonal) architecture of CLL: a clue to targeted treatment

Professor Federico Caligaris-Cappio
University Scientific Research Institute, Italy

10.30 Chemotherapy free treatment approaches: is there a role for FCR anymore in the era of targeted treatment?

Dr George Follows
Addenbrooke's Hospital, Cambridge

11.00 Clinical trials update: integrating novel therapies into NCRI portfolio

Professor Peter Hillmen
Leeds Teaching Hospitals

11.30 *Coffee*

Supportive care: Managing immune disruption

Chair: Dr Ben Kennedy

12.00 Management of autoimmune complications of CLL

Dr Claire Dearden
The Royal Marsden Hospital

12.30 Infections in CLL and avoidance strategies

Professor Paul Moss
University of Birmingham

13.00 UK CLL Trials Biobank: collaboration with Genomics England

Professor Mark Caulfield
Queen Mary, University of London

13.15 UK CLL Forum Annual General Meeting

13.15 *Lunch & Poster Viewing*

14.15 **Shortlisted Catovsky Prize Presentations**

Chair: Professor Tanja Stankovic

Reactive oxygen species are associated with anxiety in chronic lymphocytic leukaemia

Dr Adam Linley
University of Southampton

Splicing inhibition by Spliceostatin A is a promising therapeutic strategy in chronic lymphocytic leukaemia

Dr Marta Larrayoz
University of Southampton

The dual PI3K/mTOR inhibitor PF-04691502 induces substantial apoptosis in chronic lymphocytic leukaemia cells in vitro and prolongs survival in the Eμ-TCL1 mouse model

Dr Matthew Blunt
University of Southampton

In vivo PD-L1 blockade prevents leukaemia-induced T-cell dysfunction and enhances anti-tumour immunity in a mouse model of CLL

Dr Fabienne McClanahan
Queen Mary, University of London

15.15 *Coffee & Poster Viewing*

Aiming for cure

Chair: Dr Renata Walewska

15.45 Should MRD negativity still be a treatment goal?

Dr Andy Rawstron
Leeds Teaching Hospitals

16.15 The role of allogeneic transplantation in the era of small molecules

Professor Peter Dreger
University of Heidelberg, Germany

16.45 *Presentation of Prizes & Meeting Close*

Professor Daniel Catovsky

Meeting supported by educational grants from Janssen & Gilead

GlaxoSmithKline, Roche, Napp, Chugai and Lipomed have provided sponsorship towards the costs of this meeting, but have had no input into or influence over the agenda